Experimental car-t cell therapy for relapsed b-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You have B-cell lymphoma that did not respond to or came back after at least two prior treatments, including one with a CD20-targeting drug like rituximab.
- Your lymphoma cells must have a protein called CD19 on their surface (this will be checked on a tumor sample or blood test).
- You must have at least one tumor that can be measured on a scan.
- Your overall health must be good enough to undergo the treatment, with adequate organ function and an expected survival of more than 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
This trial tests a new treatment made from your own immune cells (gamma-delta T cells) that are engineered to find and kill CD19-positive lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after at least two standard treatments.
This trial tests a new type of CAR-T cell therapy (Meta10-19) for people with aggressive B-cell lymphoma that has not responded to two or more standard treatments. The therapy is designed to be more powerful inside the body to attack cancer cells.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell non-Hodgkin’s lymphoma has come back or did not respond to standard treatments. It may help your immune system attack the cancer cells that carry a specific marker called CD19.
Hear when a new Non-hodgkin Lymphoma,B Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.